/
Ovid is a biopharmaceutical company that is dedicated to developing small molecule medicines for brain disorders with significant unmet need. These potential medicines targeting the central nervous system ( CNS ) are designed to potentially halt the course of brain disease by quelling neuronal hyperexcitation and alleviating the most impactful patient symptoms.
$2.44
$0.01 (-0.41%)
EOD Jul 17, 2026
The business is unprofitable at the operating level (-585.20% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 1181.3% YoY with margins expanding 10348.5pp.
At 90x earnings, the current multiple leaves limited room for execution misses or growth deceleration. Negative free cash flow of -$38M. The business is consuming cash, not generating it.
90.4x earnings. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$7M
▲ +1181.3% YoY
Net Income (TTM)
-$24M
▲ +34.1% YoY
Op. Margin
-670.25%
▲ +10348.5pp YoY
ROIC
-31.18%
▲ +22.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$42M
▲ +31.6% YoY
Op. Cash Flow (TTM)
-$42M
▲ +31.5% YoY
Net Debt
-$142M
Net Cash Position
Cash & Equiv.
$156M
5Y CAGR: -10.5%
Continue Research
At a P/E of 90.4, Ovid Therapeutics (OVID)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Ovid Therapeutics scores 44/100 on Intrinsiqq's quality scorecard, weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Ovid Therapeutics scores 44 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -670.2% operating margin and a -31.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh OVID's valuation and scores 44/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.